Depression therapy: Future prospects

  title={Depression therapy: Future prospects},
  author={Michael Berk},
  journal={International Journal of Psychiatry in Clinical Practice},
  pages={281 - 286}
  • M. Berk
  • Published 1 January 2000
  • Psychology, Biology
  • International Journal of Psychiatry in Clinical Practice
Current biological approaches to the treatment of depression focus mainly on modification of monoaminergic neurotransmission. New agents targeting these neurotransmitters are under development. Many novel antidepressant targets are however under investigation. These include the neurokinins, glutamate, purinoceptors, opioids and trophic factors. While many of these potential targets are likely to fail clinical development, exciting novel therapeutic options are likely to emerge. 
1 Citations

Pharmacological Treatment of Patients with Schizophrenia and Substance Abuse Disorders

This article will review the medication studies that have targeted the dually diagnosed, and will also summarize the currently available pharmacological treatment options for these.



Approaches to the treatment of depression.

  • S. C. Stoner
  • Psychology, Medicine
    Journal of the American Pharmaceutical Association
  • 2002
Combining antidepressant medications with cognitive behavior therapy or psychotherapy is the optimal approach for depression, and new antidepressants with improved potency and tolerability are under development.

Recent advances in antidepressant drug therapy.

  • M. QuasimA. Kumar
  • Psychology
    International journal of psychiatry in clinical practice
  • 1999
The newer SSRI citalopram, and drugs from the SNRI, NaSSA and NAN classes, have been shown in controlled trials to be equivalent to, or more efficacious than, TCAs and/or SSRIs, and hence are better tolerated.

Novel therapeutic approaches beyond the serotonin receptor

  • R. Duman
  • Biology, Psychology
    Biological Psychiatry
  • 1998

Pindolol augmentation of antidepressant therapy

Open-label studies strongly suggest that pindolol may accelerate and augment antidepressant response, but controlled studies do not wholly support these findings: only three of six studies clearly demonstrate benefit.

Response to steroid suppression in major depression resistant to antidepressant therapy.

Some evidence is provided that steroids are involved in the maintenance of major depression, and that their suppression may lead to a readjustment of the hypothalamic-pituitary-adrenal axis with remission of the depression.

Use of slow-release melatonin in treatment-resistant depression.

SR-melatonin may be a useful adjunct for sleep, but does not substantially augment existing antidepressant therapies in some patients with treatment-resistant depression.

Ketoconazole administration in hypercortisolemic depression.

Ketoconazole, an antiglucocorticoid drug, was administered to 10 hypercortisolemic depressed patients for up to 6 weeks. Three patients dropped out because of side effects or intercurrent illness.

The role of excitatory amino acids in neuropsychiatric illness.

  • D. JavittS. Zukin
  • Psychology, Biology
    The Journal of neuropsychiatry and clinical neurosciences
  • 1990
This work has shown that neurons that contain excitatory amino acids exert descending control over subcortical structures that is behaviorally antagonistic to the effects mediated by the ascending dopaminergic system.

Neuropharmacology of St. John's Wort (Hypericum)

Hypericum extracts have only weak activity in assays related to mechanisms of the synthetic antidepressants, that is, inhibition of MAO, catechol O-methyltransferase, or serotonin reuptake.

Animal Behavioural Studies in the Evaluation of Antidepressant Drugs

Animal behavioural models of psychiatric disorders cannot exactly simulate human psychopathology, but they can be used to evaluate the behavioural changes induced by drugs and to suggest hypotheses